TGFB1 and cardiovascular disorder: Administration of a miRNA-122 inhibitor reduced the key TGF-β-induced fibrotic signaling pathway, promoted collagen synthesis, and stimulated fibrinogenesis, consequently resulting in the accumulation of fibroblasts and extracellular matrix in hypertension and cardiovascular diseases [30, 31].